Please login to the form below

vildagliptin

This page shows the latest vildagliptin news and features for those working in and with pharma, biotech and healthcare.

Novartis to make 15 drugs available at $1 a month

Among the drugs to be made available under the scheme are high blood pressure medicine valsartan, tamoxifen for breast cancer and vildagliptin for diabetes.

Latest news

AZ sues to block generic saxagliptin from Mylan

world market for DPP4 inhibitors, a class which also includes Merck &Co's market-leading Januvia (sitagliptin), Novartis' Galvus (vildagliptin) and Boehringer Ingelheim/Lilly's Trajenta (linagliptin).
Pfizer still number one - just

Meanwhile, Novartis kept the pressure on with solid performances for its own new entrants, including Gilenya (fingolimod) for multiple sclerosis, cancer drugs Afinitor/Votubia (everolimus) and Tasigna (nilotinib) and Galvus (vildagliptin)
NICE turns down Afinitor for breast cancer

for leukaemia, Galvus (vildagliptin) for diabetes and blood cancer therapy Jakavi (ruxolitinib).
Novartis lifts 2013 guidance on delay to Diovan generics

Gilenya (fingolimod), Afinitor (everolimus) for breast cancer, leukaemia therapy Tasigna (nilotinib) and Galvus (vildagliptin) for diabetes just about offsetting revenue losses to generic competition of some $800m in the quarter.
Setback for AZ and BMS as Onglyza flunks cardiovascular trial

vildagliptin). The trial was set up in the wake of new US FDA guidelines in 2009 which required pharma companies to perform cardiovascular outcome studies on new diabetes drugs.

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest appointments

bmore creative hires Kush Rach as new business director

He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Consultant Health Economics - London / Oxford: Negotiable

Senior Account Manager: Negotiable

Project / Account Manager (Medical Education): Salary TBC

Account Director: Excellent benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Consumer Health Account Director: Circa £60, 000 Gym and More

Account Director: £48, 000 - £60, 000

Events Manager – Med Comms – Surrey: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Medical Writers: Competitive Salary and Benefits

Senior Medical Writer: Great salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Associate Director: £75, 000-90, 000

Senior Medical Writer: Competitive Salary

Associate Director, Market Access & HEOR – North-West: Negotiable

Medical/ Scientific Director: Salary TBC

Medical Writers Required – Cheshire: DOE

Scientific Director / Editorial Team Leader: Great salary and benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Executive, London, Medical Communications: Excellent package

Associate Editorial Director – Med Comms – London: Salary TBC

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Director, Market Access / HEOR - North-West: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...